AMN Healthcare Q2: The Post-Strike Reality Check No One Wants to Price In

Q2 earnings from AMN Healthcare Services on the surface read like a blowout. Revenue of $673 million came in 6% above the high end of guidance. Adjusted EPS of $0.77 obliterated the consensus estimate of $0.22 — a 250% beat. Adjusted EBITDA of $73 million, or 10.9% of revenue, was up 26% year-over-year. The stock responded accordingly, jumping 16.9% on the day.

The problem is that the surface reading is wrong because it ignores what happened in Q1, what Q2 margins really contained, and what Q3 guidance tells us about the underlying business once the noise fades.

The Q1 anomaly you can't forget

To understand Q2, you need the frame. In Q1 2026, AMN Healthcare reported $1.38 billion in revenue — nearly double a normal quarter. That was not organic growth. It was driven by temporary labor disruption assignments, primarily related to nurses' strikes, which generated $722 million in revenue on their own. The strike business inflated Q1 earnings, cash flow, and margin readings across the board.

Q2 was the return to reality. Labor disruption revenue collapsed from $722 million to $25 million. Consolidated revenue fell 51% sequentially to $673 million — which, to be fair, still beat the guidance range of $620-$635 million and grew 2% year-over-year from the $658 million normal Q2 2025 run rate.

The sequential decline is obvious and management warned about it. The less obvious piece is what the Q2 margin expansion actually contained.

Q2 margins were propped by Q1's tailwinds

Q2 gross margin hit 30.6%, up 380 basis points sequentially and 210 basis points above the top end of guidance. That sounds impressive until you read the management commentary: the margin beat was supported by reserve releases and billing true-ups from Q1's labor disruption assignments. In other words, Q2's profitability was still partially funded by Q1's one-off events.

Adjust for that, and the underlying Q2 gross margin looks more like the 27-28% range the business was running before the strike cycle began. Which brings us to Q3.

Q3 guidance tells the real story

Management's Q3 guidance is the signal you should be reading most carefully:

• Revenue: $640-$655 million (1-3% YoY growth)
• Gross margin: 27.0-27.5% (down from 30.6% in Q2)
• Operating margin: 0.2-0.8% (down from 4.0% in Q2)
• Adjusted EBITDA margin: 6.5-7.0% (down from 10.9% in Q2)

Gross margin drops nearly 300 basis points. Operating margin compresses to near breakeven. EBITDA margin collapses more than 300 basis points. This is the normalized AMN Healthcare — the one that exists without strike-driven demand or the billing true-ups that lingered into Q2.

The nurse staffing business itself is growing. Nurse and Allied Solutions revenue was $422 million, up 11% year-over-year, with travel nurse volumes up 6-10% and allied up 7-8%. CEO Cary Grace called the demand acceleration "broad-based" across regions and provider sizes. The core staffing story is intact.

But the other two segments are declining. Physician and Leadership Solutions fell 6% to $165 million. Technology and Workforce Solutions dropped 15% to $87 million, with VMS (vendor management services) down 20%. Management guidance keeps them contracting in Q3: Physician down 5-7%, Technology down 11-13%. AMN is increasingly dependent on its nurse staffing franchise to carry the whole company.

Cash flow turned negative — and it hasn't finished settling

Operating cash flow in Q2 swung to negative $189.9 million, a reversal from positive $78.5 million in Q2 2025. The outflow came from returning client deposits tied to Q1's disruption assignments. Year-to-date cash flow remains positive at $372.5 million, but $117 million in client deposits remain to be settled in coming months.

That means the near-term cash flow picture stays cloudy. Each quarter's headline cash number could swing meaningfully depending on deposit settlement timing, making it harder to evaluate the underlying operating cash generation of the normalized business.

The valuation question

Here's where the comparison frame matters. AMN Healthcare trades at $36, up 128% year-to-date. It's up 122% over the last 120 days. The stock is at its 52-week high of $36.86. The momentum factor is A+ — the price has clearly responded to the earnings beats.

But trailing valuation metrics are misleading because of the GAAP accounting hit from prior-year impairment charges, which leave the trailing P/E deeply negative. The metrics that matter:

• EV/EBITDA: 9.5x on TTM basis
• Price-to-Sales: 0.41x
• Free cash flow margin: 20.7% ($670M TTM on ~$3.23B TTM revenue)

The P/S multiple looks cheap by any staffing benchmark. But the FCF of $670M is inflated by the same Q1 strike revenue that distorted earnings. The free cash flow that drove that margin was $562.5M in Q1 alone — the disruption quarter. When you normalize for the actual quarterly run rate, the FCF multiple expands materially.

The forward P/E is listed at a negative multiple because the consensus EPS model for 2026 ($2.70, including the Q1 anomaly) hasn't caught up to the reality that the rest of the year will look much more like Q2 and Q3 — lower margin, lower earnings. Zacks Rank sits at Hold, reflecting mixed earnings estimate revisions.

What the factor stack says

Putting the five-factor lens on this:

• Valuation: Looks cheap on trailing P/S (0.41x), but that multiple is distorted downward by a one-off revenue spike. Forward-looking, once the strike business fades, the normalized EV/EBITDA multiple on the Q3-guided margins could sit closer to 14-16x. That's not a screaming cheap number.
• Growth: Nurse staffing volumes are growing at a healthy clip (10% in the core travel business). But consolidated revenue growth is flat to low single-digit, and two of three segments are contracting. The growth grade is mixed.
• Profitability: Q2's 10.9% EBITDA margin is a peak reading propped by prior quarter carry-over. Q3 guidance of 6.5-7.0% EBITDA margin is the sustainable number. That's thin for a company this size. Profitability is a C-level grade at best.
• Safety: Net debt of $182 million against $362 million in cash. Leverage ratio of 1.5x. Total debt of $1.89 billion to equity of $713 million (104% debt-to-equity). The balance sheet isn't in distress but it isn't bulletproof — and the upcoming deposit settlements add near-term pressure.
• Momentum: The stock has more than doubled year-to-date. RSI at 60, well above the 50-day moving average ($32.34) and far above the 200-day ($22.66). MACD is positive. The momentum is A+ — but momentum at a 52-week high is always a leading indicator of what happens next, not a confirmation of what's happened.

AInvest's aggregate signal rates AMN as Hold, which aligns with the factor mismatch: strong momentum chasing a valuation that looks cheap only if you're measuring the wrong quarter.

The portfolio question

Here's the real question the factor stack is asking: is the market pricing AMN as a $2.7 billion normalized revenue business with expanding margins, or as a company that just rode a temporary strike cycle to a 128% gain?

If you believe the nurse staffing demand acceleration is structural — management's low contingent-to-permanent premium argument (down from 100% during COVID to mid-to-high single digits today) supports the idea that hospitals increasingly prefer flexible labor — then the Q3 guidance is a trough, not a new ceiling. The path to higher margins is real, just not immediate.

If you're more skeptical, the Q3 guidance is the new baseline: flat top-line growth, thin operating margins near breakeven, and two declining segments. At that point, a stock that has more than doubled in 12 months isn't a growth story anymore — it's a stock whose valuation has already absorbed every piece of good news the strike cycle generated.

The process says this isn't a Strong Buy. The momentum is strong, yes, but it's momentum at the 52-week high built on a Q1 anomaly that's already priced in and receding. The normalized margins are thin. The cash flow is unsettled. Two of three segments are declining.

The play if you're already in it: hold, but reduce if the price extends further without Q3 guidance improving. The trigger to reconsider is a Q3 report where EBITDA margin holds above 7% and the segment contraction story breaks — specifically, if Physician or Technology revenue stops declining.

For buyers on the sidelines: the setup doesn't offer asymmetric upside at $36. A pullback toward the $25-28 range — which would still reflect meaningful gains from the 12-month low of $15 — would offer a cleaner entry where the trailing P/S actually looks cheap again instead of looking like a lagging measure of a stock that's already run.

The rally is real. The question is whether the factor stack that drove it is still intact or whether valuation has caught up and the rest is coasting on Q1 momentum.

What to watch next: Q3 revenue and margin execution against the $640-655M / 6.5-7.0% EBITDA guidance range. Whether the $117M in remaining client deposits settles without creating further cash flow volatility. Whether nurse staffing demand that management says strengthened in July translates into visible volume growth, or whether the broad-based demand narrative starts to show regional cracks.